Xilio Therapeutics Inc (XLO): Price-to-Revenue Ratio

Brandmark of xiliotx.com (XLO)

Xilio Therapeutics, Inc. (XLO) possesses high profit potential based on the scalable synthesis of targeted oncology drugs. The price-to-sales valuation on GURU.Markets reflects the asset's dynamics, where the parameter value reaches 1.00. Financial stability is ensured by the prudent allocation of the R&D budget, while the development strategy relies on organic growth and synergies from partner licensing agreements.

Xilio Therapeutics, Inc. (XLO): Price-to-Revenue Ratio from 08/10/2024 to 11/16/2026

Xilio Therapeutics, Inc. (XLO) - metric breakdowns and financial figures

- stock exchange capitalization data:
General company analysis:Xilio, XLO
Finished products of Xilio

The P/S ratio reflects the relationship between the market capitalization of Xilio Therapeutics, Inc. (XLO) and its total revenue, measuring the premium the market is willing to pay per unit of sales. This metric determines the asset's investment attractiveness through a balance of capital protection and potential growth. For Xilio Therapeutics, Inc. (XLO), this indicator is speculative in nature, as the absence of commercial products shifts the valuation toward future FDA approvals. By analyzing the divergence of the P/S ratio from its historical average on GURU.Markets, an investor assesses current market expectations regarding the company's future pricing power.

Competing companies

ONC - Price to Sales|P/S Multiple HALO (Halozyme Therapeutics, Inc.)|Revolution Medicines (RVMD) - Price to Sales|ascentage.com - P/S Multiple|Market Capitalization-to-Revenue Ratio CGON (cgoncology.com)|URGN: P/S Multiple|Bicara Therapeutics Inc (BCAX) - P/S Multiple|Price-to-Revenue Ratio personalis.com|Market Cap to Revenue Erasca Corp (ERAS)|Market Cap to Revenue DCTH (Delcath)|Price-to-Revenue Coefficient Y-mAbs Therapeutics, Inc.|P/S Multiple AURA (Aura Biosciences Inc)|Market Capitalization-to-Revenue Ratio CADL|ARAY: Market Cap to Revenue|Price-to-Revenue Coefficient sellaslifesciences.com SLS|ACTU (Actuate Therapeutics, Inc) - Market Cap to Revenue|Market Cap to Revenue Ratio CTOR|Price-to-Revenue Ratio TuHURA Biosciences Inc.|TARA: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Fate Therapeutics (FATE)|Price-to-Revenue Coefficient Aadi Bioscience|Price-to-Revenue Ratio TScan Therapeutics Inc TCRX|CSBR: Market Cap to Revenue Ratio|XBIT: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio CVM (cel-sci.com)|OSTX: P/S Multiple|Price to Sales Radiopharm Theranostics Ltd (RADX)|ARTV (Artiva) - P/S Multiple|Market Cap to Revenue Ratio ANL (Adlai Nortye)|Price-to-Revenue Ratio Veru Pharma (VERU)|P/S Multiple Tempest Tx (TPST)|P/S Multiple RENB (Enochian BioSciences)|Mural Bio - Price-to-Revenue Ratio|KAPA - Price-to-Revenue Ratio|OnKure Therapeutics (OKUR) - Market Cap to Revenue|GDTC: P/S Multiple|Price to Sales Curis Corp (CRIS)|APLM (apollomicsinc.com) - P/S Multiple|Market Cap to Revenue Tharimmune Corp (THAR)|P/S Multiple ADVB|GNPX - Price to Sales|Price-to-Revenue Ratio calidibio.com CLDI|SBFM - Market Cap to Revenue|XBIO - Price-to-Revenue Ratio|SLRX: Price-to-Revenue Ratio|Purple Biotech (PPBT) - Price-to-Revenue Ratio|AON - Market Capitalization-to-Revenue Ratio|Market Cap to Revenue BGNE|P/S Multiple Checkpoint Therapeutics Inc.|P/S Multiple ELEV|Market Cap to Revenue iCAD ICAD|P/S Multiple IKNA (Ikena Oncology, Inc.)|Market Capitalization-to-Revenue Ratio NTBL|Viracta Therapeutics, Inc. - P/S Multiple|Market Capitalization-to-Revenue Ratio MOR (MorphoSys Inc)|NAYA (NAYA Biosciences Inc) - Market Cap to Revenue|Market Cap to Revenue Ascentage Pharma Group Ltd